Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this study is to determine if delta-haemolysin production deficiency of Staphylococcus aureus is a marker in favour of chronic infections on implants
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Deficiency of delta-hemolysine | Implant infected by Staphylococcus aureus with delta-haemolysin Production Deficiency |
| |
| Presence of delta-hemolysine | Implant infected by Staphylococcus aureus with delta-haemolysin Production |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Delta-haemolysin | Other | comparison of groups having infection with S. aureus with and without delta-haemolysin Production |
|
| Measure | Description | Time Frame |
|---|---|---|
| Rate of infection with or witout delta-haemolysin in Staphylococcus Aureus | patients, profile of the bacterium, medical and chirurgical treatment, rate. comparison between the 2 groups | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption |
| Measure | Description | Time Frame |
|---|---|---|
| Rate of Treatment Failure | Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin. Analyse of risk factor. Comparison between the 2 groups | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
patients having implant infection due to S. aureus treated by DAIR managed at the Lyon Bone and joint infection reference Center between 2006 and 2018
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Johanna Boulant, CRA | Contact | johanna.boulant@chu-lyon.fr |
| Name | Affiliation | Role |
|---|---|---|
| FLORENT VALOUR, Md,PhD | Hospices Civils de Lyon | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospices Civils de Lyon | Recruiting | Lyon | 69004 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D013203 | Staphylococcal Infections |
| D000088562 | Persistent Infection |
| ID | Term |
|---|---|
| D016908 | Gram-Positive Bacterial Infections |
| D001424 | Bacterial Infections |
| D001423 | Bacterial Infections and Mycoses |
| D007239 | Infections |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C025994 | delta hemolysin protein, Staphylococcus aureus |
Not provided
Not provided
Not provided